Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Alzheimer's Disease: Treatment01:22

Alzheimer's Disease: Treatment

Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
Atherosclerosis III: Management01:26

Atherosclerosis III: Management

Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
Atherosclerosis IV: Nursing Management01:23

Atherosclerosis IV: Nursing Management

Nursing management for a patient with arteriosclerosis involves a comprehensive approach focusing on lifestyle modification, disease monitoring, education, and symptomatic care. Here is an overview of effective nursing strategies:Assessment and Monitoring: Initial and ongoing assessments are crucial. Nurses must document the patient's medical history, including any hypertension, diabetes, hyperlipidemia, and other cardiovascular diseases. Assessments also cover family history and lifestyle...
Alzheimer's Disease: Overview01:26

Alzheimer's Disease: Overview

Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ and tau...
Amyloid Fibrils03:03

Amyloid Fibrils

Amyloid fibrils are aggregates of misfolded proteins.  Under most circumstances, misfolded proteins are either refolded by chaperone proteins or degraded by the proteasome. However, in the case of a mutation or a disease, these proteins can accumulate to form large clusters and often further assemble to form elongated fibers, called fibrils. 
Amyloid deposits were observed as early as 1639 in the liver and the spleen.   In 1854, Rudolph Virchow performed iodine staining, normally used to...
Amyloid Fibrils03:03

Amyloid Fibrils

Amyloid fibrils are aggregates of misfolded proteins.  Under most circumstances, misfolded proteins are either refolded by chaperone proteins or degraded by the proteasome. However, in the case of a mutation or a disease, these proteins can accumulate to form large clusters and often further assemble to form elongated fibers, called fibrils. 
Amyloid deposits were observed as early as 1639 in the liver and the spleen.   In 1854, Rudolph Virchow performed iodine staining, normally used to...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Prediction of appropriate implantable cardioverter-defibrillator therapy using machine learning and routinely available clinical data.

European heart journal. Digital health·2026
Same author

Correction: Circulating nitric oxide pathway metabolites in heart failure with preserved ejection fraction: a sex-stratified cross-sectional analysis.

Biology of sex differences·2026
Same author

Stroke and its consequences: protocol and pilot data of the observational Berlin Long-term Observation of Vascular Events (BeLOVE) stroke stratum.

BMJ neurology open·2026
Same author

A pilot study on AI-based voice analysis for monitoring patients hospitalized with acute decompensated heart failure.

European heart journal. Digital health·2026
Same author

Fasciculations Following COVID-19 Vaccination-A Case Series of Ten Patients.

Vaccines·2026
Same author

Efficacy of a Voice Biomarker for the Prediction of Heart Failure Hospitalisation: Results from the Telemedical Interventional Management in Heart Failure III (TIM-HF3) Voice Study.

European journal of heart failure·2026

Related Experiment Video

Updated: May 28, 2026

Imaging Amyloid Tissues Stained with Luminescent Conjugated Oligothiophenes by Hyperspectral Confocal Microscopy and Fluorescence Lifetime Imaging
10:04

Imaging Amyloid Tissues Stained with Luminescent Conjugated Oligothiophenes by Hyperspectral Confocal Microscopy and Fluorescence Lifetime Imaging

Published on: October 20, 2017

Wearables for Telemonitoring in ATTR-Amyloidosis: Current Perspectives.

Andreas Kind1,2,3,4, Helena Pernice2,4,5, Gina Barzen2,4,6

  • 1Deutsches Herzzentrum der Charité (DHZC), Department of Cardiology, Angiology and Intensive CareMedicine, Charité Virchow Klinikum, 13353 Berlin, Germany.

Sensors (Basel, Switzerland)
|May 27, 2026
PubMed
Summary
This summary is machine-generated.

Wearable sensors show promise for monitoring transthyretin amyloidosis (ATTR), a progressive disease. Further research is needed to validate these digital biomarkers for clinical use.

Keywords:
atrial fibrillationgait analysisheart failureneuropathysensorstelemonitoringtransthyretin amyloidosiswearables

More Related Videos

Eye-Tracking Control to Assess Cognitive Functions in Patients with Amyotrophic Lateral Sclerosis
07:00

Eye-Tracking Control to Assess Cognitive Functions in Patients with Amyotrophic Lateral Sclerosis

Published on: October 13, 2016

Related Experiment Videos

Last Updated: May 28, 2026

Imaging Amyloid Tissues Stained with Luminescent Conjugated Oligothiophenes by Hyperspectral Confocal Microscopy and Fluorescence Lifetime Imaging
10:04

Imaging Amyloid Tissues Stained with Luminescent Conjugated Oligothiophenes by Hyperspectral Confocal Microscopy and Fluorescence Lifetime Imaging

Published on: October 20, 2017

Eye-Tracking Control to Assess Cognitive Functions in Patients with Amyotrophic Lateral Sclerosis
07:00

Eye-Tracking Control to Assess Cognitive Functions in Patients with Amyotrophic Lateral Sclerosis

Published on: October 13, 2016

Area of Science:

  • Cardiovascular Medicine
  • Digital Health
  • Biomarker Discovery

Background:

  • Transthyretin amyloidosis (ATTR) is a progressive multisystem disease impacting the cardiovascular and neurological systems.
  • ATTR is characterized by arrhythmias, conduction issues, hemodynamic instability, autonomic dysfunction, and gait abnormalities.
  • These multifaceted symptoms suggest ATTR is a suitable candidate for multimodal wearable monitoring.

Purpose of the Study:

  • To review current knowledge on wearable sensor applications in amyloidosis, using ATTR as a model.
  • To assess the feasibility of using digital biomarkers from related conditions for ATTR.
  • To identify challenges in developing and implementing wearable monitoring for ATTR.

Main Methods:

  • Literature review of current studies on wearable monitoring in ATTR and related cardiovascular/neurological conditions.
  • Evaluation of signal-based biomarker extraction from electrocardiographic, photoplethysmographic, and inertial sensor data.
  • Analysis of methodological and implementation challenges for wearable technology in ATTR.

Main Results:

  • ATTR-specific data are limited, primarily from small studies on rhythm monitoring and functional assessments.
  • Metrics like atrial fibrillation burden, activity patterns, gait variability, and heart rate variability show potential.
  • ATTR's structural changes and high arrhythmia burden may complicate conventional digital biomarker interpretation, requiring disease-specific approaches.

Conclusions:

  • Wearable monitoring in ATTR is technically feasible and biologically plausible but currently investigational.
  • Standardized, phenotype-stratified studies are essential to link wearable data to clinical outcomes.
  • Routine integration into care pathways requires further validation of wearable-derived characteristics.